MedTrace Logo

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

NCT06169202 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-12-13

No results posted yet for this study

Summary

This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer.

Conditions

Interventions

DEVICE

fruquintinib

4 mg orally once daily, D1-14, repeated every 3 weeks.

DRUG

Irinotecan

180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).

DRUG

Capecitabine

1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.

Sponsors & Collaborators

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, PhD · First Hospital of China Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-04-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06169202 on ClinicalTrials.gov